- For Patients
- Introduction to the Marshall Protocol
- Length of the MP
- Immunopathology
- Managing immunopathology
- Food and drink
- Light restriction
- Vitamin D metabolite calculator - get feedback on vitamin D results
- Therapeutic probe - best method for determining MP suitability
- Starting the Marshall Protocol
- Resources for patients
- Marshall Protocol summary
- Palliative vs. curative treatments
- Patient interviews on Bacteriality
- Non-MP treatments
- Glossary
- The Protocol
- Marshall Protocol summary
- Publications and presentations
- Science behind immunopathology
- Science behind olmesartan (Benicar)
- Safety of olmesartan
- Resources for physicians
- Vitamin D metabolite calculator - get feedback on vitamin D results
- Therapeutic probe - best method for determining MP suitability
- Physicians' concerns about the MP
- Notice for emergency medical personnel
- The Pathogenesis
- Publications and presentations
- Science behind Marshall Pathogenesis
- Microbes in the human body
- Successive infection and variability in disease
- Autoimmune theory of disease
- Science behind vitamin D
- Metabolism of vitamin D and the VDR
- Th1 Spectrum Disorder - how chronic inflammatory diseases are related
- Transmission of bacteria and onset of chronic disease
- Evolutionary perspective on disease
- Incidence and prevalence of disease
- Evidence that chronic disease is caused by pathogens
- Diseases
- Foundation
- Related Sites
Paper - Vitamin D metabolites as clinical markers in autoimmune and chronic disease
Type: Paper
Authors: Greg Blaney, MD, Paul J. Albert, Amy D. Proal
Publication: Annals of the New York Academy of Sciences
Citation: . Vitamin D metabolites as clinical markers in autoimmune and chronic disease. Ann N Y Acad Sci. 2009 Sep;1173:384-90. doi: 10.1111/j.1749-6632.2009.04875.x.
[PMID: 19758177] [DOI: 10.1111/j.1749-6632.2009.04875.x]
<html>
<a href=“https://autoimmunityResearch.org/preprints/BlaneyAnnals2009Preprint.pdf”><img src=“https://mpkb.org/_media/home/downloadpdf.gif” class=“pdfbutton” /></a>
</html>
Abstract
Recent research has implicated vitamin D deficiency (serum levels of 25-hydroxyvitamin D <50nmol/L) with a number of chronic conditions including autoimmune conditions such as multiple sclerosis, lupus, psoriasis and chronic conditions such as osteoporosis, osteoarthritis, metabolic syndrome, fibromyalgia and chronic fatigue syndrome. It has been assumed that low levels of 25-hydroxyvitamin D (25-DThe vitamin D metabolite widely (and erroneously) considered best indicator of vitamin D "deficiency." Inactivates the Vitamin D Nuclear Receptor. Produced by hydroxylation of vitamin D3 in the liver.) accurately indicate vitamin D storage and vitamin D receptorA nuclear receptor located throughout the body that plays a key role in the innate immune response. (VDR) mediated control of calcium metabolism and innate immunityThe body's first line of defense against intracellular and other pathogens. According to the Marshall Pathogenesis the innate immune system becomes disabled as patients develop chronic disease.. To evaluate this assumption, 25-D and 1,25-dihydroxyvitamin D3 (1,25-DPrimary biologically active vitamin D hormone. Activates the vitamin D nuclear receptor. Produced by hydroxylation of 25-D. Also known as 1,25-dihydroxycholecalciferol, 1,25-hydroxyvitamin D and calcitirol.) levels were measured in 100 Canadian patients with these conditions. Additionally, other inflammatory markers (CK, CRP) were measured. Results showed a strong positive association between these autoimmune conditions and levels of 1,25-D >110 pmol/L. However, there was little association with vitamin D deficiency or the other inflammatory markers. These findings support the use of 1,25-D as a clinical marker in autoimmune conditions. It also suggests either a disruption of the controlling cytochrome P450 enzymes and/or reduced VDR responsiveness in these conditions. Finally, the results challenge the assumption that measurement of 25-D is an accurate index of vitamin D metabolism.